A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
Georg Golor1, Ke Hu2, Matthieu Ruffin3, Alexandra Buchelt3, Emmanuel Bouillaud3, Yanfeng Wang2, Mario Maldonado31Parexel International GmbH, Berlin, Germany; 2Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Novartis Pharma AG, Basel, SwitzerlandAbstract: Pasireotide (SOM230) is a multireceptor-tar...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2012-04-01
|
| Seri Bilgileri: | Drug Design, Development and Therapy |
| Online Erişim: | http://www.dovepress.com/a-first-in-man-study-to-evaluate-the-safety-tolerability-and-pharmacok-a9739 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|